Pfizer recalls valsartan drug after possible carcinogen present

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Derek Brumby)
(Image: Getty/Derek Brumby)

Related tags: Pfizer, Japan, valsartan, Sartan, Recall, carcinogen

Pfizer Japan recalls its high blood pressure drug containing the API valsartan after possible carcinogenic impurities were found.

Over 763,000 tablets were taken off the shelf, as the high blood pressure drug Amvalo (valsartan amlodipine besilate) was recalled due to contamination.

The tablets were manufactured in an undisclosed factory based in India between April and July 2018, and are subject to recall after the company’s review, which came after Japanese Health Ministry asked pharmaceutical firms to check whether any of their drugs using valsartan contained any carcinogenic impurities.

In a statement from Pfizer Japan, there have been no reports of any patients experiencing complications after taking the drug.

“We sincerely apologize for causing troubles and worries to all including those who engage in medical care. We will fully pay careful attention to our manufacturing and quality control to prevent a recurrence,”​ Akihisa Harada, president of Pfizer Japan, said in the statement.

The company’s president went on to say that the Pfizer subsidiary will pay careful attention to its manufacturing and quality control to prevent a recurrence.

While the company did not disclose the impurity, multiple sartan​ (valsartan, Iosartan, and irbesartan) recalls have been tied to the contamination of two possible carcinogens​: N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA).

The US Food and Drug Administration recently made a statement regarding the identification of NDMA and NDEA in certain medicines, like that of Amvalo, and noted that the impurities may be formed from the reuse of solvents during the manufacturing process.

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Follow us


View more